The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
Open accessAbstract
BACKGROUND: Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's disease is characterized by progressive muscle weakness and loss of respiratory function, leading to early death. We conducted a randomized, placebo-controlled trial of alglucosidase alfa, a recombinant human GAA, for the treatment of late-onset Pompe's disease. METHODS: Ninety patients who were 8 years of age or older, ambulatory, and free of invasive ventilation were randomly assigned to receive biweekly intravenous alglucosidase alfa (20 mg per kilogram of body weight) or placebo for 78 weeks at eight centers in the United States and Europe. The two primary end points were distance walked during a 6-minute walk test and percentage of predicted forced vital capacity (FVC). RESULTS: At 78 weeks, the estimated mean changes from baseline in the primary end points favored alglucosidase alfa (an increase of 28.1+/-13.1 m on the 6-minute walk test and an absolute increase of 3.4+/-1.2 percentage points in FVC; P=0.03 and P=0.006, respectively). Similar proportions of patients in the two groups had adverse events, serious adverse events, and infusion-associated reactions; events that occurred only in patients who received the active study drug included anaphylactic reactions and infusion-associated reactions of urticaria, flushing, hyperhidrosis, chest discomfort, vomiting, and increased blood pressure (each of which occurred in 5 to 8% of the patients). CONCLUSIONS: In this study population, treatment with alglucosidase alfa was associated with improved walking distance and stabilization of pulmonary function over an 18-month period. (ClinicalTrials.gov number, NCT00158600.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Spirometric Reference Values from a Sample of the General U.S. Population
HANKINSON, J. L., ODENCRANTZ, J. R., & FEDAN, K. B. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9712108 · Cited by 4,206
ATS/ERS Statement on Respiratory Muscle Testing
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.166.4.518 · Cited by 2,841
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease
Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000251268.41188.04 · Cited by 781
Self-citationvan der Ploeg, A. T., & Reuser, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61555-x · Cited by 756
Self-citationKishnani, P. S., Hwu, W.-L., Mandel, H., Nicolino, M., Yong, F., & Corzo, D. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.11.033 · Cited by 598
Self-citationvan den Hout, H. M. P., Hop, W., van Diggelen, O. P., Smeitink, J. A. M., Smit, G. P. A., Poll-The, B.-T. T., Bakker, H. D., Loonen, M. C. B., de Klerk, J. B. C., Reuser, A. J. J., et al. (2003) · Pediatrics · doi:10.1542/peds.112.2.332 · Cited by 555
Self-citationClinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients
Hagemans, M. L. C. (2005) · Brain · doi:10.1093/brain/awh384 · Cited by 364
Amalfitano, A., Bengur, A. R., Morse, R. P., Majure, J. M., Case, L. E., Veerling, D. L., Mackey, J., Kishnani, P., Smith, W., McVie-Wylie, A., et al. (2001) · Genetics in Medicine · doi:10.1038/gim200127 · Cited by 347
Self-citationEarly Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease
Kishnani, P. S., Corzo, D., Leslie, N. D., Gruskin, D. J., van der Ploeg, A., Clancy, J. P., Parini, R., Morin, G., Beck, M., Bauer, M., et al. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181b24e94 · Cited by 343
Self-citationRecombinant human α-glucosidase from rabbit milk in Pompe patients
Van den Hout, H., Reuser, A. J., Vulto, A. G., Christa B Loonen, M., Cromme-Dijkhuis, A., & Van der Ploeg, A. T. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02533-2 · Cited by 330
Self-citationNicolino, M., Byrne, B., Wraith, J. E., Leslie, N., Mandel, H., Freyer, D. R., Arnold, G. L., Pivnick, E. K., Ottinger, C. J., Robinson, P. H., et al. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e31819d0996 · Cited by 293
Self-citationKishnani, P. S., Nicolino, M., Voit, T., Rogers, R. C., Tsai, A. C.-H., Waterson, J., Herman, G. E., Amalfitano, A., Thurberg, B. L., Richards, S., et al. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.02.035 · Cited by 282
Self-citationThurberg, B. L., Lynch Maloney, C., Vaccaro, C., Afonso, K., Tsai, A. C.-H., Bossen, E., Kishnani, P. S., & O'Callaghan, M. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700484 · Cited by 261
Self-citationStrothotte, S., Strigl-Pill, N., Grunert, B., Kornblum, C., Eger, K., Wessig, C., Deschauer, M., Breunig, F., Glocker, F. X., Vielhaber, S., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5275-3 · Cited by 256
Müller-Felber, W., Horvath, R., Gempel, K., Podskarbi, T., Shin, Y., Pongratz, D., Walter, M. C., Baethmann, M., Schlotter-Weigel, B., Lochmüller, H., et al. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.06.002 · Cited by 244
Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up
Winkel, L. P. F., Van den Hout, J. M. P., Kamphoven, J. H. J., Disseldorp, J. A. M., Remmerswaal, M., Arts, W. F. M., Loonen, M. C. B., Vulto, A. G., Van Doorn, P. A., De Jong, G., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20019 · Cited by 233
Self-citationJuvenile and adult-onset acid maltase deficiency in France: Genotype–phenotype correlation
Laforêt, P., Nicolino, M., Eymard, B., Puech, J. P., Caillaud, C., Poenaru, L., & Fardeau, M. (2000) · Neurology · doi:10.1212/wnl.55.8.1122 · Cited by 216
Self-citationClinical features of late‐onset Pompe disease: A prospective cohort study
Wokke, J. H. J., Escolar, D. M., Pestronk, A., Jaffe, K. M., Carter, G. T., van den Berg, L. H., Florence, J. M., Mayhew, J., Skrinar, A., Corzo, D., et al. (2008) · Muscle & Nerve · doi:10.1002/mus.21025 · Cited by 175
Self-citationNeutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
Wang, J., Lozier, J., Johnson, G., Kirshner, S., Verthelyi, D., Pariser, A., Shores, E., & Rosenberg, A. (2008) · Nature Biotechnology · doi:10.1038/nbt.1484 · Cited by 170
Muscular weakness assessment: Use of normal isometric strength data
The National Isometric Muscle Strength (NIMS) Database Consortium (1996) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(96)90188-4 · Cited by 167
Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy
Mayhew, J. E., Florence, J. M., Mayhew, T. P., Henricson, E., Leshner, R. T., McCarter, R., Escolar, D. M., & and The CINRG Investigators (2006) · Muscle & Nerve · doi:10.1002/mus.20654 · Cited by 123
Self-citationLate-onset Pompe disease primarily affects quality of life in physical health domains
Hagemans, M. L. C., Janssens, A. C. J. W., Winkel, L. P. F., Sieradzan, K. A., Reuser, A. J. J., van Doorn, P. A., & van der Ploeg, A. T. (2004) · Neurology · doi:10.1212/01.wnl.0000142597.69707.78 · Cited by 111
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease
van der Beek, N. A. M. E., Hagemans, M. L. C., Reuser, A. J. J., Hop, W. C. J., van der Ploeg, A. T., van Doorn, P. A., & Wokke, J. H. J. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.11.007 · Cited by 109
van Capelle, C. I., Winkel, L. P. F., Hagemans, M. L. C., Shapira, S. K., Arts, W. F. M., van Doorn, P. A., Hop, W. C. J., Reuser, A. J. J., & van der Ploeg, A. T. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.04.009 · Cited by 99
Flexible Sample Size Considerations Using Information-Based Interim Monitoring
Mehta, C. R., & Tsiatis, A. A. (2001) · Drug Information Journal · doi:10.1177/009286150103500407 · Cited by 95
Amalfitano, A., Bengur, A. R., Morse, R. P., Majure, J. M., Case, L. E., Veerling, D. L., Mackey, J. F., Kishnani, P. S., Smith, W. E., McVie-Wylie, A. J., et al. (2001) · Genetics in Medicine · doi:10.1097/00125817-200103000-00008 · Cited by 91
Self-citationTowards a molecular therapy for glycogen storage disease type II (Pompe disease)
Chen, Y., & Amalfitano, A. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01694-4 · Cited by 48
Progress in enzyme replacement therapy in glycogen storage disease type II
Angelini, C. I., Semplicini, C., Tonin, P., et al. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285609103324 · Cited by 30
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
McDonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J., Eagle, M., Gappmaier, E., Glanzman, A. M., PTC124‐GD‐007‐DMD Study Group, Spiegel, R., Barth, J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23905 · Cited by 354
Self-citationTranscription factor EB (TFEB) is a new therapeutic target for Pompe disease
Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202176 · Cited by 341
Structure of human lysosomal acid α-glucosidase–a guide for the treatment of Pompe disease
Roig-Zamboni, V., Cobucci-Ponzano, B., Iacono, R., Ferrara, M. C., Germany, S., Bourne, Y., Parenti, G., Moracci, M., & Sulzenbacher, G. (2017) · Nature Communications · doi:10.1038/s41467-017-01263-3 · Cited by 317
Metadata
- Authors
- van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., Lange, D. J., Leshner, R. T., Mayhew, J. E., Morgan, C., Nozaki, K., Park, D. J., Pestronk, A., Rosenbloom, B., Skrinar, A., van Capelle, C. I., van der Beek, N. A., Wasserstein, M., & Zivkovic, S. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-04-15
- Volume
- 362
- Issue
- 15
- Pages
- 1396-1406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159490726
- Cited by
- 745
- References
- 30
- FWCI
- 39.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.